



# Strategies to Mitigate Risk of Recurrent Viremia Among People Who Inject Drugs (PWID) Successfully Treated for HCV Infection

Holeksa J, Magel T, Thiam A, Truong D, Yung R, Chu L, Conway B

*Vancouver Infectious Diseases Centre*

# Disclosures


- Julie Holeksa has received travel grants from AbbVie.
- Tianna Magel has nothing to disclose.
- Dr. Astou Thiam has received travel grants from AbbVie.
- Letitia Chu has nothing to disclose.
- Rossitta Yung has nothing to disclose.
- Dr. David Truong has received honoraria from Merck and Co.
- Dr. Brian Conway has received grants, honoraria, travel funding, and holds advisory board positions with AbbVie, Merck & Co, Gilead Sciences and ViiV.

# Background/aims

- People who inject drugs (PWID) remain at risk of recurrent viremia (RV) following successful treatment of HCV infection
- Strategies to reduce the occurrence of RV must be incorporated into all HCV treatment programs aimed at this population

# Methods


- PWID treated with DAA's maintained in long-term follow-up
- All were enrolled in long-term multidisciplinary care
- Documentation of ongoing risk behaviours for HCV acquisition with appropriate plan of intervention
- Systematic measurement of HCV RNA every 6 months, more frequently as clinically indicated
- Endpoint: documentation of RV and its correlates



# Results

- 323 PWID SVR<sub>12</sub> in long-term follow-up
- Mean follow-up: 633 days
- 4 cases of recurrent viremia
- RV cases were:
  - 53 years old (49-57 years)
  - Male
  - All active PWID
  - Rate: 0.63 cases/100 person years
  - 2 individuals currently undergoing retreatment
  - SVR preserved in 98.8% cases

Long-term follow-up PWID



Demographics	PWID DAA; n=323
Mean age (years)	54 (22-79)
Female (n,%)	80 (25)
Tx Naïve (n,%)	254 (79)
Current Injection Drug use (n,%)	189 (59)
Cirrhotic (n,%)	52 (16)
GT1 (n,%)	212 (66)

# Conclusions/implications

- Low rates of reinfection among high risk individuals maintained in long-term multidisciplinary care
- Cost-effectiveness of accepting a higher rate of reinfection vs. preventing it

Initial engagement



Multi-disciplinarity



Durability



# Acknowledgements

- VIDC patients, staff and supporters who are committed to the success of the program.

THANK YOU!